Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting

被引：0
|
作者：
Murthy, Rashmi Krishna
Varma, Ankur
Mishra, Priyankana
Hess, Kenneth R.
Young, Elliana J.
Murray, James L.
Koenig, Kimberly Higginbotham
Green, Marjorie C.
Moulder, Stacy L.
Melhem-Bertrandt, Amal
Booser, Daniel J.
Valero, Vicente
Hortobagyi, Gabriel N.
Esteva, Francisco J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527
引用
收藏
页数：1
相关论文
共 50 条
  • [1] OUTCOMES OF PATIENTS WITH HER2-POSITIVE BREAST CANCER METASTATIC TO BRAIN TREATED WITH HER2-TARGETED SYSTEMIC THERAPY AND STEREOTACTIC RADIOSURGERY
    Shumway, John
    Torras, Marina
    Reeder-Hayes, Katherine
    Jolly, Trevor
    Dees, Elizabeth
    Ray, Emily
    Muss, Hyman
    Carey, Lisa
    Shen, Colette
    [J]. NEURO-ONCOLOGY, 2021, 23 : 41 - 41
  • [2] Outcomes of Patients With HER2-Positive Breast Cancer Metastatic to Brain Treated With HER2-Targeted Systemic Therapy and Stereotactic Radiosurgery
    Shumway, J. W.
    Torras, M.
    Hayes, K. Reeder
    Jolly, T.
    Dees, E. C.
    Ray, E. M.
    Carey, L. A.
    Shen, C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E580 - E580
  • [3] Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
    Kunte, Siddharth
    Abraham, Jame
    Montero, Alberto J.
    [J]. CANCER, 2020, 126 (19) : 4278 - 4288
  • [4] Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).
    Berghoff, A.
    Bartsch, R.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rudas, M.
    Pluschnig, U.
    Wiltschke, C.
    Gnant, M.
    Steger, G. G.
    Zielinski, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy
    Brufsky, Adam
    Zulfiqar, Malik
    Peguero, Julio
    Lathrop, Kate
    Bhat, Gajanan
    Lebel, Francois
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [7] Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy
    Badve, S. S.
    Li, L.
    Thorat, M. A.
    Gagnon, R. C.
    Ellis, C. E.
    O'Shaughnessy, J.
    Blackwell, K. L.
    Baselga, J.
    Sledge, G. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab
    Yuri Torrejon, Davis
    Di Cosimo, Serena
    Sanchez-Olle, Gessami
    Balmana, Judith
    Bellet, Meritxell
    Gomez, Patricia
    Saura, Cristina
    Manuel Perez-Garcia, Jose
    Munoz-Couselo, Eva
    Vidal, Maria
    Ortega, Vanesa
    De Mattos-Arruda, Leticia
    Oliveira, Mafalda
    Mulet-Margalef, Nuria
    Tabernero, Josep
    Cortes, Javier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [10] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
12345